David Pelizzon Sells 4,000 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 4,000 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $25.75, for a total value of $103,000.00. Following the completion of the sale, the director owned 6,897,764 shares of the company’s stock, valued at $177,617,423. The trade was a 0.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

OrthoPediatrics Price Performance

NASDAQ:KIDS opened at $23.32 on Friday. The business’s 50-day simple moving average is $21.32 and its two-hundred day simple moving average is $18.62. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The stock has a market cap of $608.89 million, a PE ratio of -13.88 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. As a group, analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

Large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in OrthoPediatrics by 397.1% in the 2nd quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock worth $87,000 after acquiring an additional 3,637 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of OrthoPediatrics during the 2nd quarter valued at approximately $4,636,002,000. Grandeur Peak Global Advisors LLC bought a new position in shares of OrthoPediatrics during the 2nd quarter valued at approximately $954,000. Bank of America Corp DE purchased a new position in shares of OrthoPediatrics in the second quarter valued at $268,000. Finally, AWM Investment Company Inc. purchased a new position in shares of OrthoPediatrics in the second quarter valued at $4,537,000. Institutional investors own 69.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KIDS. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. BTIG Research lifted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Finally, Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average target price of $26.44.

More OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.